ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 123 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.18 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,700,980 | -28.9% | 683,000 | 0.0% | 0.00% | -25.0% |
| Q2 2023 | $19,267,430 | +64.0% | 683,000 | 0.0% | 0.00% | +100.0% |
| Q1 2023 | $11,747,600 | -14.6% | 683,000 | 0.0% | 0.00% | -33.3% |
| Q4 2022 | $13,755,620 | -7.0% | 683,000 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $14,794,000 | -22.9% | 683,000 | 0.0% | 0.00% | -25.0% |
| Q2 2022 | $19,192,000 | -39.1% | 683,000 | 0.0% | 0.00% | -20.0% |
| Q1 2022 | $31,514,000 | -45.1% | 683,000 | 0.0% | 0.01% | -44.4% |
| Q4 2021 | $57,413,000 | +26.1% | 683,000 | 0.0% | 0.01% | +12.5% |
| Q3 2021 | $45,515,000 | +27.7% | 683,000 | +1.9% | 0.01% | +33.3% |
| Q2 2021 | $35,644,000 | +122.0% | 670,000 | +81.1% | 0.01% | +100.0% |
| Q1 2021 | $16,054,000 | -63.6% | 370,000 | -56.5% | 0.00% | -66.7% |
| Q4 2020 | $44,149,000 | +103.4% | 850,000 | +28.0% | 0.01% | +80.0% |
| Q3 2020 | $21,706,000 | +0.4% | 664,000 | +47.6% | 0.01% | 0.0% |
| Q2 2020 | $21,609,000 | – | 450,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,664,409 | $177,556,000 | 4.47% |
| Avidity Partners Management LP | 2,493,800 | $166,187,000 | 3.68% |
| Matrix Capital Management Company, LP | 4,349,279 | $289,836,000 | 3.30% |
| Integral Health Asset Management, LLC | 90,000 | $5,998,000 | 1.72% |
| Affinity Asset Advisors, LLC | 77,500 | $5,165,000 | 1.30% |
| Ghost Tree Capital, LLC | 65,000 | $4,332,000 | 1.27% |
| Ikarian Capital, LLC | 200,000 | $13,328,000 | 0.94% |
| HighVista Strategies LLC | 20,596 | $1,373,000 | 0.91% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 23,855 | $1,590,000 | 0.90% |
| Woodline Partners LP | 507,847 | $33,843,000 | 0.55% |